CTS will implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
On August 9, 2019, the new CTS Laboratory Information System was successfully implemented in St...
After a recent reevaluation of the Monolisa anti-HBs EIA package insert, the CTS QA/Scientific team ...
Honor Your StaffCelebrate Lab Week, and honor yourself and your colleagues as a vital part of the la...
We are informing you that the FDA has announced their withdrawal of Guidance for ZIKV Testing. In th...
As a friendly reminder, airlines often change their routine flights and cargo hours for holidays. We...
TEMPE, Ariz. (Sept. 8, 2022) — Marion Lanteri, Ph.D., began this week as Creative Testing Solu...